At Rush University Medical Center, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.
Pain Management Following Total Hip Arthroplasty Study
Patients undergoing total hip arthroplasty will be randomized to one of two groups. Group 1 will consist of a standard post-operative epidural infusion of 0.1% bupivacaine, 5 mL/hr continuous infusion with 1 mL every 15 minutes as a bolus option. Group 2 will consist of a programmed intermittent epidural bolus of 5 mL every hour with 1 mL every 15 minutes as a bolus option. Both groups of patients will be allowed to have oral opioids and adjuvants following their surgery.
In order to participate you must meet the following criteria:
- Have total hip replacement surgery scheduled.
- Are between the ages of 18 and 89.
You will be excluded from the study if any of the following criteria apply to you:
- Have a history of prior lumbar spine surgery.
- Have a history of bleeding disorder or current use of anticoagulant/antiplatelet agents.
Have a history of opioid tolerance defined as the following:
- At least 60 mg of oral morphine/daily
- At least 25 mcg transdermal fentanyl/hour
- At least 30 mg of oral oxycodone daily
- At least 8 mg oral hydromorphone daily
- At least 25 mg oral oxymorphone daily
- An equianalgesic dose of another opioid daily for a week or longer
- Are allergic to or have a documented reaction to bupivacaine or amide local anesthetics.
- Have a disability or impairment such that using a patient-controlled bolus would not be possible.
- Have surgeon-specified perioperative procedures that precludes the current study’s protocol.
This is a partial list of inclusion and exclusion criteria.